Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States.
FAIL · Does not pass the screen
4.45 USD
Price as of 27 Oct 2026Daily close, not a live quote
Screened 2026-10-27 · the tape above runs as of 16:04 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price4.45 USD at the 27 Oct 2026 close
Our ratingAvoid, current read distribution
Ethical screenDoes not pass
OptionsOpen interest leans heavily to calls (put/call 0.02)
Last reviewed27 Oct 2026 (2 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 4.45 against the desk's fair-value range, base estimate 2.22, over the last year.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.02, read 2026-10-28
Ethical does not pass the values gate
Price4.45 USD
Fair value2.22
Ethical score10.0/100
RatingAVOID
Our investment reviews on this name
2026-10-25Read Distribution4.65-4.3% to today ✓Markdown gives way to Distribution after a 15% slide in 5 weeks
2026-09-19Read Markdown5.46-18.5% to today ✓Distribution gives way to Markdown with volume flow in agreement
2026-08-20Read Distribution5.46-18.5% to today ✓Markup gives way to Distribution
2026-07-02Read Markup5.46-18.5% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Abeona Therapeutics Inc. holds its Distribution at $4.45. Consolidating, no directional conviction, held for 27 days.
As held on the ledger · 2026-10-27
Phase
Distribution · caution
Quantitative state
Consolidating, no directional conviction, held for 27 days
Price at the screen
$4.45
Valuation
5.61 trailing · 23.63 forward price to earnings
Values screen
FAIL· score 10.0
Beta
1.34
The Workings
Five Screens, Shown in Full
Does not pass. Cash ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
7.82%
Below 33%
Interest-bearing debt is just 7.8% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
59.98%
Below 33%
Interest-bearing cash and securities are 60.0% of assets, above the one-third limit.
Fail
Receivables
0.00%
Below 49%
Money owed to the company is 0.0% of assets, under the 49% limit.
Pass
Revenue purity
95.46%
Below 5%
95.5% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Abeona Therapeutics's business is fine, but its cash and interest-bearing securities are about 60% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when ABEO's ethical verdict changes
Today ABEO does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads AVOID: it trades above our $2.22 fair value estimate, strong competitive moat.
Fair value range in USD, drawn from the 2026-10-27 screen. The gold marker is the market price at the same screen. The price runs 50.0% above the base estimate.
Third-party analyst targets: 7 covering, consensus Strong Buy. The average target sits +340% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-27 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it gives us pause
At 23.6x forward earnings, the price already runs ahead of the business. It trades 50% above our $2.22 fair value, so you would be buying at a premium, not a discount. The strong moat is real, but quality alone does not make an expensive price cheap.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ABEO trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 13% above its long-term trend line with momentum reading oversold. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (7 analysts) rates it strong buy, with a mean price target of $20.
2026-10-18Markdown$4.65-18.0%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 18.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (7 analysts) rates it strong buy, with a mean price target of $20.
2026-10-11Markdown$5.67+0.0%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (7 analysts) rates it strong buy, with a mean price target of $20.
2026-10-02Markdown$5.67+3.8%Entry 8
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 3.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (7 analysts) rates it strong buy, with a mean price target of $20.
2026-09-19Markdown · changed$5.46+0.0%Entry 7
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (7 analysts) rates it strong buy, with a mean price target of $20.
2026-08-20Distribution · changed$5.46+0.0%Entry 6
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (7 analysts) rates it strong buy, with a mean price target of $20.
2026-07-20Markup$5.46+0.0%Entry 5
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (7 analysts) rates it strong buy, with a mean price target of $20.
2026-07-18Markup$5.46+0.0%Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (7 analysts) rates it strong buy, with a mean price target of $20.
2026-07-16Markup$5.46+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 17%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (7 analysts) rates it strong buy, with a mean price target of $20.
2026-07-03Markup$5.46+0.0%Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.